Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay
Fine Closes ‘Pay-For-Delay’ Investigation That Began In 2011
Executive Summary
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.
You may also be interested in...
EU Anti-Competition Crackdown Boosts Access To Affordable Drugs, Commission Finds
A report from the European Commission highlights how the enforcement of pharmaceutical antitrust rules between 2018 and 2022 increased the availability of fairly priced innovative medicines in the bloc.
EU Anti-Competition Crackdown Boosts Access To Affordable Drugs, Commission Finds
A report from the European Commission highlights how the enforcement of pharmaceutical antitrust rules between 2018 and 2022 increased the availability of fairly priced innovative medicines in the bloc.
European Commission Targets Teva Over Alleged Copaxone Antitrust Breach
A European Commission investigation into Teva’s conduct over its Copaxone multiple sclerosis drug has led to the firm receiving a statement of objections, which details a preliminary finding that the company violated EU antitrust laws.